Monitor upcoming patent litigation outcomes for ENTYVIO, which generated JPY 958,042 million in revenue (21% of total), as adverse rulings could materially impact future sales. Track resolution of the DOJ investigation into TRINTELLIX marketing practices for potential financial penalties.
Price Chart
Executive Summary
Takeda filed its annual report (FY ended March 31, 2026) via Form 6-K, disclosing total revenue of JPY 4,505,720 million and basic EPS of JPY 121.75. The filing includes JPY 129,266 million in impairment losses, including JPY 58,173 million from discontinuing cell therapy research and JPY 31,877 million related to ALUNBRIG, plus JPY 70,818 million in restructuring expenses. The filing also notes ongoing patent revocation proceedings for ENTYVIO in the UK and Netherlands, and a DOJ investigation into TRINTELLIX marketing practices. No prior-year comparative financials are provided, preventing YoY growth analysis.
Key Facts
- Total revenue for FY ended March 31, 2026: JPY 4,505,720 million
- Basic EPS: JPY 121.75
- Impairment losses of JPY 129,266 million, including JPY 58,173 million from discontinuing gamma delta T-cell therapy platform and JPY 31,877 million related to ALUNBRIG
- Restructuring expenses of JPY 70,818 million from enterprise-wide efficiency program
- Goodwill of JPY 5,809,010 million and intangible assets of JPY 3,419,348 million on balance sheet
- Patent revocation proceedings initiated against ENTYVIO patents in UK and Netherlands (Feb-Apr 2026)
- DOJ Civil Investigative Demand regarding TRINTELLIX off-label promotion and Anti-Kickback Statute violations
- Share buyback completed: 23,367 thousand shares for JPY 99,956 million
- Proposed dividend of JPY 100.00 per share for record date March 31, 2026
- No prior-year comparative financial data provided in this filing
Financial Impact
Revenue JPY 4,505,720 million; EPS JPY 121.75; impairments JPY 129,266 million; restructuring JPY 70,818 million
Risk Factors
- ENTYVIO patent revocation proceedings in UK and Netherlands could threaten key revenue driver
- DOJ investigation into TRINTELLIX off-label promotion may result in penalties or compliance costs
- Large goodwill and intangible asset base (JPY 9.2 trillion combined) exposes balance sheet to future impairment risk
- Ongoing restructuring program may indicate persistent cost pressures
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001395064-26-000160 |
| Document: form6k_052626x2.htm | 0001395064-26-000160 |
| Document: 0001395064-26-000160-index-headers.html | 0001395064-26-000160 |
| Document: 0001395064-26-000160-index.html | 0001395064-26-000160 |
| Document: 0001395064-26-000160.txt | 0001395064-26-000160 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 9, 2026 20w ago | 6-K | $31.30 $32.48 | ▲ +3.77% | ▲ +1.97% | $41.22 (+31.69%) |
Jun 5, 2026 20w ago | 6-K | $30.47 $34.28 | ▼ −12.50% | ▼ −11.93% | $41.22 (−35.28%) |
Jun 5, 2026 20w ago | 6-K | $30.47 $34.28 | ▼ −12.50% | ▼ −11.93% | $41.22 (−35.28%) |
Jun 1, 2026 21w ago | 6-K | $30.47 $30.47 | · 0.00% | ▲ +2.75% | $41.22 (+35.28%) |
May 26, 2026 22w ago | 6-K | $32.10 $30.47 | ▼ −5.08% | ▼ −6.29% | $41.22 (+28.41%) |
May 26, 2026 22w ago | 6-K | $32.10 $30.47 | ▼ −5.08% | ▼ −6.29% | $41.22 (+28.41%) |
May 26, 2026 22w ago | 6-K | $32.10 $30.47 | ▼ −5.08% | ▼ −6.29% | $41.22 (+28.41%) |
May 26, 2026 22w ago | 6-K | $32.10 $30.47 | ▲ +5.08% | ▲ +6.29% | $41.22 (−28.41%) |
May 19, 2026 23w ago | 6-K | $32.26 $32.10 | ▲ +0.50% | ▲ +2.79% | $41.22 (−27.77%) |
May 13, 2026 23w ago | 6-K | $32.68 $32.26 | ▼ −1.29% | ▼ −0.13% | $41.22 (+26.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers